Inactive Instrument

Company Venn Life Sciences Holdings London S.E.

Equities

GB00B9275X97

Biotechnology & Medical Research

Business Summary

hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO plc runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialized on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

Sales per Business

GBP in Million2021Weight2022Weight Delta
Contract Research Organisation Pharmaceutical Services
95.6 %
- - 48 95.6 % -
Other
4.4 %
- - 2 4.4 % -

Sales per region

GBP in Million2021Weight2022Weight Delta
United Kingdom, Ireland, France and Netherlands
100.0 %
39 100.0 % 51 100.0 % +29.98%

Managers

Managers TitleAgeSince
Chief Executive Officer 55 21-10-12
Founder 37 11-01-31
Director of Finance/CFO 61 17-06-30
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer 68 -
Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 57 22-06-07
Founder 73 18-11-30
Director/Board Member 63 20-11-23
Chief Executive Officer 55 21-10-12
Director of Finance/CFO 61 17-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 680,371,877 413,459,011 ( 60.77 %) 0 60.77 %

Shareholders

NameEquities%Valuation
JPMorgan Asset Management (UK) Ltd.
5.170 %
35,176,858 5.170 % 11 M p
Canaccord Genuity Wealth Ltd.
3.186 %
21,680,000 3.186 % 7 M p
21,159,177 3.110 % 7 M p
20,702,209 3.043 % 7 M p
Octopus Investments Ltd.
2.083 %
14,175,000 2.083 % 5 M p
Gresham House Asset Management Ltd.
1.870 %
12,726,146 1.870 % 4 M p
Thornbridge Investment Management LLP
1.465 %
9,966,084 1.465 % 3 M p
Mandarine Gestion SA
1.029 %
7,000,000 1.029 % 2 M p
4,017,270 0.5905 % 1 M p
Livingbridge EP LLP
0.4965 %
3,378,042 0.4965 % 1 M p

Company contact information

hVIVO PLC

21 Plumbers Row

E1 1EQ, London

+

address Venn Life Sciences Holdings